Security Type | Security Class Title | Fee Calculation or Carry Forward Rule | Amount Registered | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee | Carry Forward Form Type | Carry Forward File Number | Carry Forward Initial Effective Date | Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward | |
| Newly Registered Securities | ||||||||||||
Fees to Be Paid | Equity | Common Stock, par value $0.001 per share | Other | 1,081,332 (1) | $11.16(2) | $12,067,665.12(2) | $147.60 per $1,000,000 | $1,781.19 | ||||
Fees Previously Paid | — | — | — | — | — | — | — | — | ||||
| Carry Forward Securities | ||||||||||||
Carry Forward Securities | — | — | — | — | — | — | — | — | — | — | — | — |
| Total Offering Amounts | $12,067,665.12(2) | — | $1,781.19 | |||||||||
| Total Fees Previously Paid | — | |||||||||||
| Total Fee Offsets | $1,027.06(3) | |||||||||||
| Net Fee Due | $754.13(3) | |||||||||||
| Registrant or Filer Name | Form or Filing Type | File Number | Initial Filing Date | Filing Date | Fee Offset Claimed | Security Type Associated with Fee Offset Claimed | Security Title Associated with Fee Offset Claimed | Unsold Securities Associated with Fee Offset Claimed | Unsold Aggregate Offering Amount Associated with Fee Offset Claimed | Fee Paid with Fee Offset Source | |
| Rule 457(p) | |||||||||||
| Fees Offset Claims | Gyre Therapeutics, Inc. | S-3 | 333-275466 | November 13, 2023 | $1,027.06(3) | Equity | Common Stock, par value $0.001 per share | 1,081,333(3) | $6,958,377.86 | ||
| Fees Offset Sources | Gyre Therapeutics, Inc. | S-3 | 333-275466 | November 13, 2023 | $1,027.06 | ||||||
| (1) | The shares of common stock will be offered for resale by GNI USA, Inc. (the “Selling Stockholder”) pursuant to the prospectus contained in the registration statement to which this exhibit is attached. The registration statement registers the resale of an aggregate of 1,081,332 shares of the registrant’s common stock, consisting of (i) 540,666 shares of the registrant’s common stock issued upon the conversion of the registrant’s Series X Convertible Preferred Stock, par value $0.001 per share (“Convertible Preferred Stock”) effective January 23, 2024, held by the Selling Stockholder and (ii) 540,666 shares of the registrant’s common stock issuable upon the conversion of Convertible Preferred Stock pursuant to the exercise of warrants issued to the Selling Stockholder. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), the shares of common stock being registered hereunder include such indeterminate number of shares of common stock as may be issuable upon stock splits, stock dividends, or other distribution, recapitalization or similar events. |
| (2) | This estimate is made pursuant to Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The proposed maximum offering price per share and maximum aggregate offering price are based upon the average of the high and low sales prices of the registrant’s common stock on May 28, 2024, as reported on The Nasdaq Capital Market. |
| (3) | The Registrant previously paid $1,027.06 in registration fees with respect to the registration statement on Form S-3 filed on November 13, 2023 (No. 333-275466) (the “Withdrawn Registration Statement”). The Registrant filed a Form RW to withdraw the Withdrawn Registration Statement on November 29, 2023. |
